Lecanemab (Leqembi)

About Eisai

Eisai is a Japanese pharmaceutical giant with a strong commitment to human health care (hhc), focusing on addressing unmet medical needs in neurology, oncology, and neglected tropical diseases. The company has achieved significant breakthroughs in Alzheimer's treatment with Lecanemab and maintains a robust oncology portfolio including multi-targeted kinase inhibitors. Eisai is also deeply committed to global health initiatives, providing treatments for neglected tropical diseases in developing countries while maintaining strong financial performance as a publicly traded company.

About BioArctic AB

BioArctic is a publicly traded Swedish biotech company at the forefront of developing novel treatments for neurodegenerative disorders. Its most significant achievement is the co-development of lecanemab (Leqembi®) with Eisai, which became the first amyloid-targeting therapy to receive traditional FDA approval for Alzheimer's disease. The company leverages its proprietary BrainTransporter® technology to develop antibodies and other biologics that can cross the blood-brain barrier, with a pipeline extending beyond Alzheimer's to Parkinson's disease and other CNS conditions. BioArctic's strategy combines proprietary research with strategic partnerships to advance its clinical programs.

Therapeutic Areas

Other Alzheimer's Disease Drugs